Skip to main content
. 2019 Apr 18;3:PO.18.00327. doi: 10.1200/PO.18.00327

FIG 1.

FIG 1.

Landscape of genomic alterations across 51 patients with ductal prostate cancer. Each column represents one patient. Pathogenic mutations were those predicted to either activate oncogenic signaling pathways (eg, WNT- or PI3K-signaling) or inactivate tumor suppressors (eg, DNA damage repair [DDR] genes, TP53). HR, homologous recombination; MMR, mismatch repair; VUS, variant of uncertain significance.